Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Figure 1

FcγRIIIA polymorphism genotyping. Upper line: patient homozygous for the FcγRIIIA p.158 V-allele, 2nd line: patient homozygous for the FcγRIIIA p.158 F-allele, lower line: heterozygous for the FcγRIIIA p.158 V and F-allele.